Global Oncology Antibody Drug Conjugates Market

2022-04-28 11:58:47 UTC | Healthcare & Pharmaceuticals

According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027.

Browse 155 Market Data Tables and 133 Figures spread through 156 Pages and in-depth TOC on “Global oncology antibody drug conjugates Market - Forecast to 2027’’ https://www.globalmarketestimates.com/market-report/oncology-antibody-drug-conjugates-market-3781

Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical, BioAtla, Bicycle Therapeutics, ADC Therapeutics, Genmab, Helix BioPharma, CytomX, and Innate Pharma, among others, are the some of the key players in the oncology antibody drug conjugates market

Indication Size Outlook (Revenue, USD Billion, 2022-2027)

·         Breast Cancer

·         Ovarian Cancer

·         Cervical Cancer

·         NSCLC

·         Colorectal Cancer

·         Pancreatic Cancer

·         Hodgkin Lymphoma

·         Leukemia

·         Gastric Cancer

·         Others

Regional Outlook (Revenue, USD Billion, 2022-2027)

North America                                                                                 

• The U.S.
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Australia
• Rest of APAC

Central & South America

• Brazil
• Argentina
• Rest of CSA

Middle East & Africa

• Saudi Arabia
• UAE
• Rest of MEA

 

Contact: Yash Jain

Email address: yash.jain@globalmarketestimates.com

Phone Number: +1 6026667238